In a large primary care data set, the CHA2DS2-VASc score leads to an almost universal recommendation for anticoagulation treatment in those aged ≥65 years with atrial fibrillation.

Autor:	Orchard, Jessica J, Giskes, Katrina, Orchard, John W, La Gerche, Andre, Neubeck, Lis, Hespe, Charlotte, Lowres, Nicole, Freedman, Ben
Předmět:	STROKE prevention STROKE ORAL drug administration AGE distribution ATRIAL fibrillation ANTICOAGULANTS RISK assessment PRIMARY health care DATABASE management RESEARCH funding DESCRIPTIVE statistics DECISION making in clinical medicine MEDICAL practice DISEASE risk factors OLD age
Zdroj:	European Journal of Cardiovascular Nursing; Nov2023, Vol. 22 Issue 8, p769-772, 4p
Abstrakt:	Graphical Abstract From 2012 to 2016, the oral anticoagulant (OAC) treatment determination for atrial fibrillation (AF) patients moved from the CHADS2 score to the CHA2DS2-VASc score. A data set collated during previous studies (2011–19) with de-identified data extracted from clinical records at a single timepoint for active adult patients (n = 285 635; 8294 with AF) attending 164 general practices in Australia was analysed. The CHA2DS2-VASc threshold (score ≥2 men/≥3 women) captured a significantly higher proportion than CHADS2≥2 (all ages: 85 vs. 68%, P < 0.0001; ≥65 years: 96 vs. 76%, P < 0.0001). The change from CHADS2 to CHA2DS2-VASc resulted in a significantly higher proportion of AF patients being recommended OAC, driven by the revised scoring for age. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu